These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9859692)

  • 21. Clinical applications of zolmitriptan (Zomig, 311C90).
    Lipton RB; Stewart WF
    Cephalalgia; 1997 Oct; 17 Suppl 18():53-9. PubMed ID: 9399017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zolmitriptan (Zomig).
    Rapoport AM; Bigal ME; Tepper SJ; Sheftell FD
    Expert Rev Neurother; 2004 Jan; 4(1):33-41. PubMed ID: 15853613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet.
    Dowson AJ; Charlesworth BR
    Int J Clin Pract; 2003 Sep; 57(7):573-6. PubMed ID: 14529055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers.
    Dixon R; Gillotin C; Gibbens M; Posner J; Peck RW
    Br J Clin Pharmacol; 1997 Mar; 43(3):273-81. PubMed ID: 9088582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient preference for triptan formulations: a prospective study with zolmitriptan.
    Dowson A; Bundy M; Salt R; Kilminster S
    Headache; 2007 Sep; 47(8):1144-51. PubMed ID: 17883519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population.
    Sheftell FD; Feleppa M; Tepper SJ; Volcy M; Rapoport AM; Bigal ME
    Headache; 2004; 44(7):661-8. PubMed ID: 15209687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Symptomatic treatment of migraine with zolmitriptan: experience with 82 patients].
    Pascual J; Navarro A; Caminero AB; Jurado C; Díaz-Insa S; Huerta M
    Neurologia; 2006 May; 21(4):188-91. PubMed ID: 16832773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig).
    Proietti-Cecchini A; Afra J; Schoenen J
    Cephalalgia; 1997 Dec; 17(8):849-54; discussion 799. PubMed ID: 9453273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. International 311C90 Long-Term Study Group.
    Zagami AS
    Neurology; 1997 Mar; 48(3 Suppl 3):S25-8. PubMed ID: 9071267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild.
    Klapper J; Lucas C; Røsjø Ø; Charlesworth B;
    Cephalalgia; 2004 Nov; 24(11):918-24. PubMed ID: 15482352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
    Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
    Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period.
    Thomsen LL; Dixon R; Lassen LH; Gibbens M; Langemark M; Bendtsen L; Daugaard D; Olesen J
    Cephalalgia; 1996 Jun; 16(4):270-5. PubMed ID: 8792040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine.
    Allais G; Acuto G; Cabarrocas X; Esbri R; Benedetto C; Bussone G
    Neurol Sci; 2006 May; 27 Suppl 2():S193-7. PubMed ID: 16688629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Part IV: effects of zolmitriptan orally disintegrating tablet on migraine symptoms and ability to perform normal activities: a post-marketing surveillance study in Germany.
    Diener HC; Gendolla A
    Curr Med Res Opin; 2005; 21 Suppl 3():S18-24. PubMed ID: 16083520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical safety of 311C90: aggregated data from patients and volunteers to date.
    Earl NL
    Eur Neurol; 1996; 36 Suppl 2():8-12. PubMed ID: 8791026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Zolmitriptan in treatment of migraine attack--the ARES Study].
    Sturzenegger M; Daems K; Billeter M
    Schweiz Med Wochenschr; 2000 Dec; 130(51-52):1984-93. PubMed ID: 11688066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Almotriptan and zolmitriptan in the acute treatment of migraine.
    Goadsby PJ; Massiou H; Pascual J; Diener HC; Dahlöf CG; Mateos V; Dowson AJ; Raets I; Cunha L; Färkkilä M; Manzoni GC
    Acta Neurol Scand; 2007 Jan; 115(1):34-40. PubMed ID: 17156263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists.
    Ferrari MD
    Neurology; 1997 Mar; 48(3 Suppl 3):S21-4. PubMed ID: 9071266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers.
    Smith DA; Cleary EW; Watkins S; Huffman CS; Polvino WJ
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):301-5. PubMed ID: 9660035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide.
    Seaber EJ; Ridout G; Layton G; Posner J; Peck RW
    Eur J Clin Pharmacol; 1997; 53(3-4):229-34. PubMed ID: 9476036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.